KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report)’s share price passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $9.52 and traded as low as $8.75. KalVista Pharmaceuticals shares last traded at $9.16, with a volume of 179,794 shares changing hands. Analyst Ratings Changes […]
Jefferies Financial Group Inc. bought a new stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Rating) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 1,200,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $8,112,000. Jefferies Financial Group Inc. owned approximately 4.87% of […]
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Rating) CFO Benjamin L. Palleiko sold 4,037 shares of the company’s stock in a transaction dated Thursday, May 18th. The stock was sold at an average price of $10.14, for a total value of $40,935.18. Following the completion of the transaction, the chief financial officer now directly owns 78,126 […]
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Rating) CFO Benjamin L. Palleiko sold 4,037 shares of the stock in a transaction on Thursday, May 18th. The shares were sold at an average price of $10.14, for a total value of $40,935.18. Following the sale, the chief financial officer now directly owns 78,126 shares in the company, […]
Denali Advisors LLC bought a new stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Rating) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 10,800 shares of the specialty pharmaceutical company’s stock, valued at approximately $73,000. A number of other hedge funds also recently added […]